How to obtain the free drug of Vemurafenib/Zobov and what is the specific process?

As a first-line targeted therapy for BRAF V600 mutation-positive unresectable or metastatic melanoma, Vemurafenib has been approved for marketing in China and has been included in the National Medical Insurance List. This means that patients can significantly reduce their financial burden after prescriptions from medical institutions and purchasing drugs through medical insurance. However, for some patients, additional assistance can still be obtained by applying for the "Donate Drug Program" through official or partner institutions.

Drug donation policies are usually initiated by drug manufacturers (such as Roche Pharmaceuticals) or their public welfare cooperation platforms, aiming to help patients with long-term medication and financial difficulties continue their treatment. The general process includes three core links: First, the patient must be diagnosed with BRAF V600 mutation-positive unresectable or metastatic melanoma under the guidance of a doctor, and have completed medical insurance reimbursement and drug purchase records. Subsequently, the attending doctor will issue relevant diagnostic certificates and treatment recommendations. Secondly, patients or family members can submit an application through an assistance project platform authorized by pharmaceutical companies (such as the Patient Assistance Foundation), attaching proof of income, medical insurance settlement statements, copies of medical records and other materials. After passing the review, those who meet the conditions can enter the drug donation cycle. Finally, donated drugs are distributed by designated pharmacies or logistics agencies, and patients need to be reviewed on schedule to confirm their condition and medication compliance to renew their eligibility for donated drugs.

It is worth noting that drug donation projects usually have clear requirements for patients’ financial conditions, medical insurance usage, and treatment cycles, and policies vary slightly in different regions. It is recommended that patients consult the hospital pharmacist or official customer service before applying to confirm the latest process and material list.

Overall, with the official launch of vemurafenib in China and its coverage by medical insurance, patients can minimize financial pressure and achieve long-term standardized treatment through medical insurance reimbursement and drug donation plans. The improvement of the targeted drug donation mechanism not only reflects the improvement of medical fairness, but also promotes the popularization and accessibility of precision treatment in the country.

Reference: https://www.drugs.com/mtm/vemurafenib.html